Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study

Kihyun Kim, MD PhD, Jin Seok Kim, MD PhD, Sung-Soo Yoon, MD PhD, Dok-Hyun Yoon, MD PhD, HyeonSeok Eom, MD PhD, Je-Jung Lee, MD PhD, Hyeonwoo Yim, MD PhD, Misun Park, MS, Hojoon Lee, DRPH,MDMPH,PhD, Chang Ki Min, MD PhD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-136242

Published: 2020

Journal Articles

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

Jae-Cheol Jo, MD, Ho Sup Lee, MD, Cheolwon Suh, Hye Jin Kang, MD PhD, Won Seog Kim, MD PhD, HyeonSeok Eom, MD PhD, Inho Kim, MD PhD, Ho-Jin Shin, MD PhD, Yong Park, Won Sik Lee, MD PhD, Young Rok Do, PhDMD, Lee Gyeong-Won, Sung Yong Oh, Sung-Nam Lim, MD, Seong Yoon Lee, MD

Blood (2019) 134 (Supplement_1): 2884.

https://doi.org/10.1182/blood-2019-132192

Published: 2019

Journal Articles

A Prospective Registry Study of Peg-G-CSF Prophylaxis for Patients with Diffuse Large B-Cell Lymphoma (CISL 1403)

Blood (2017) 130 (Supplement 1): 2840.

https://doi.org/10.1182/blood.V130.Suppl_1.2840.2840

Published: 2017

Journal Articles

Final Report on Phase II Trial of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (Methotrexate, Ifosfamide, Etoposide, Dexamethasone, and L-asparaginase) Chemotherapy for Patients with Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type

Dok Hyun Yoon, MD PhD, Seok Jin Kim, MD PhD, Seong Hyun Jeong, MD, Dong-Yeop Shin, MD, Sung Hwa Bae, MD, Junshik Hong, MD, Seong Kyu Park, MD, Ho-Young Yhim, MD, Deok-Hwan Yang, MD, Hye Won Lee, MD, Mark Lee, MD PhD, Hyeonseok Eom, MD, PhD, Jae-Yong Kwak, MD PhD, Jae Hoon Lee, Cheolwon Suh, Won Seog Kim, MD PhD

Blood (2015) 126 (23): 3942.

https://doi.org/10.1182/blood.V126.23.3942.3942

Published: 2015

Journal Articles

A New Prognostic Model for Multiple Myeloma Patients in the Era of Novel Agents

Hyungwoo Cho, MD, Dok Hyun Yoon, MD PhD, Kihyun Kim, Sung-Soo Yoon, Chang-Ki Min, MD, PhD, HyeonSeok Eom, MD, PhD, Jin Seok Kim, Je-Jung Lee, Jae Hoon Lee, Cheolwon Suh

Blood (2015) 126 (23): 4185.

https://doi.org/10.1182/blood.V126.23.4185.4185

Published: 2015

Journal Articles

Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial

Blood (2015) 126 (23): 4240.

https://doi.org/10.1182/blood.V126.23.4240.4240

Published: 2015

Journal Articles

Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Bortezomib, Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with Autologous Stem Cell Transplantation and Maintenance Treatment with Bortezomib for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase II Trial.

Sung-Soo Yoon, Hye Jin Kim, Joo Seop Chung, HyeonSeok Eom, Jun-Ho Jang, Hye Jin Kang, Cheol Soo Kim, Kihyun Kim, Dongsoon Lee, Jae Hoon Lee, Junglim Lee, Sang Jae Lee, Yoo Hong Min, Chu-Myong Seong, Sang-Kyun Sohn, Cheolwon Suh, Jong-Ho Won

Blood (2008) 112 (11): 3330.

https://doi.org/10.1182/blood.V112.11.3330.3330

Published: 2008

Journal Articles

Velcade ® , Thalidomide, Dexamethasone (VTD) Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment Demonstrates High Response Rates for High-Risk Patients with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Updated Results of Phase II Trial

HyeonSeok Eom, Yeo-Kyeoung Kim, Joo-Seop Chung, Kihyun Kim, Hyo-Jung Kim, HoYoung Kim, Jong-Youl Jin, Young-Rok Do, Suk-Joong Oh, Cheolwon Suh, Chu-Myong Seong, Chul Soo Kim, Dong Soon Lee, Jae Hoon Lee

Blood (2008) 112 (11): 2785.

https://doi.org/10.1182/blood.V112.11.2785.2785

Published: 2008

Journal Articles

DNA Repair Gene, XRCC1 P olymorphisms Are Associated with Chemotherapy Induced Toxicity in Patients with Diffuse Large B Cell Lymphoma Who Received Frontline R-CHOP Chemotherapy.

In-Suk Kim, Gyeong-Won Lee, Hoon-Gu Kim, Sun-Young Kong, MD, PhD, HyeonSeok Eom, MD, PhD

Blood (2008) 112 (11): 1620.

https://doi.org/10.1182/blood.V112.11.1620.1620

Published: 2008

Journal Articles

Low Incidence of Thromboembolism in Asian Multiple Myeloma Patients Treated with Thalidomide: Do We Really Need Prophylaxis for Thromboembolism in Asian Population?

Youngil Koh, Soo-Mee Bang, MD, PhD, Jae Hoon Lee, Hwi-Joong Yoon, Young-Rok Do, PhD, Hun-Mo Ryoo, Nari Lee, Seok Jin Kim, MD, PhD, Sung-Soo Yoon, MD, PhD, Jong-Ho Won, MD, PhD, Yeung-Chul Mun, MD, PhD, Moon-Hee Lee, Jong-Youl Jin, MD, PhD, Hyo-Jung Kim, HyeonSeok Eom, MD, PhD, Min Kyoung Kim, MD, Hyun Chun Shin, Korean Multiple Myeloma Working Party

Blood (2008) 112 (11): 5146.

https://doi.org/10.1182/blood.V112.11.5146.5146

Published: 2008

Journal Articles

Velcade®, Thalidomide, Dexamethasone (VTD) Induction Therapy Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment for the Patients (pts) with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Early Analysis from the Korean Multiple Myeloma Working Party.

HyeonSeok Eom, Yeo-Kyeoung Kim, Jooseop Chung, Kihyun Kim, HyoJeong Kim, JongYul Jin, Young-Rok Do, Sukjoong Oh, HoYoung Kim, Cheolwon Suh, Chu-Myong Seong, Chul Soo Kim, Dong Soon Lee, Jae Hoon Lee

Blood (2007) 110 (11): 4831.

https://doi.org/10.1182/blood.V110.11.4831.4831

Published: 2007

Journal Articles

Clinical Features and Treatment Outcomes of Primary Testicular Lymphoma.

Byeong-Bae Park, MD, Jong Gwang Kim, MD,PhD, HyeonSeok Eom, MD,PhD, Hyo Jin Kim, MD,PhD, Hyuck Chan Kwon, MD,PhD, Sung Yong Oh, MD, Jung Hun Kang, MD, Suk Joong Oh, MD,PhD, Ho-Jin Shin, MD,PhD, Cheolwon Suh, MD,PhD, Jung Han Kim, MD, Ho Young Kim, MD, Sang Cheol Lee, MD, Kihyun Kim, MD,PhD, Chul W. Jung, MD,PhD, Won Seog Kim, MD,PhD

Blood (2006) 108 (11): 4670.

https://doi.org/10.1182/blood.V108.11.4670.4670

Published: 2006

NARROW

Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study

Open-Labeled, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients with High Risk Diffuse Large B Cell Lymphoma (DLBCL): Borma Trial from Consortium for Improving Survival of Lymphoma (CISL)

A Prospective Registry Study of Peg-G-CSF Prophylaxis for Patients with Diffuse Large B-Cell Lymphoma (CISL 1403)

Final Report on Phase II Trial of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (Methotrexate, Ifosfamide, Etoposide, Dexamethasone, and L-asparaginase) Chemotherapy for Patients with Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type

A New Prognostic Model for Multiple Myeloma Patients in the Era of Novel Agents

Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial

Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Bortezomib, Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with Autologous Stem Cell Transplantation and Maintenance Treatment with Bortezomib for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase II Trial.

Velcade ® , Thalidomide, Dexamethasone (VTD) Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment Demonstrates High Response Rates for High-Risk Patients with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Updated Results of Phase II Trial

DNA Repair Gene, XRCC1 P olymorphisms Are Associated with Chemotherapy Induced Toxicity in Patients with Diffuse Large B Cell Lymphoma Who Received Frontline R-CHOP Chemotherapy.

Low Incidence of Thromboembolism in Asian Multiple Myeloma Patients Treated with Thalidomide: Do We Really Need Prophylaxis for Thromboembolism in Asian Population?

Velcade®, Thalidomide, Dexamethasone (VTD) Induction Therapy Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment for the Patients (pts) with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Early Analysis from the Korean Multiple Myeloma Working Party.

Clinical Features and Treatment Outcomes of Primary Testicular Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only